Gilead Activates Its Pipeline: Option Exercises at Cartography Bio and Kymera Signal Accelerating Oncology Execution

oncodaily - In a pair of announcements that underscore Gilead Sciences’ intensifying commitment to oncology, two of its collaboration partners, Cartography Biosciences and Kymera Therapeutics, revealed today that Gilead has exercised exclusive […]

AI Summary: Gilead moved to accelerate its oncology strategy by exercising option agreements with smaller biotech partners, including Kymera and Cartography Bio. The moves signal targeted investment in protein degraders and other novel modalities, shoring up the company’s mid‑stage pipeline and hinting that big pharma still prefers buying options to inventing overnight.

#pharmaceuticals #biotech #mergersandacquisitions #drugdevelopment #oncology #cancerresearch #clinicaltrials #venturecapital
Pharmaceuticals RSSBiotech RSSMergers and Acquisitions RSSDrug Development RSSOncology RSSCancer Research RSSClinical Trials RSSVenture Capital RSS

KRAS-targeting PROTAC drug passes first clinical test

4 months / nature / Karen O’Leary

Vivatides gets $54M; Wegovy drops cold chain in EU; Gilead takes Kymera option

4 months / endpoints / ENDPOINTS

Gilead Activates Its Pipeline: Option Exercises at Cartography Bio and Kymera Signal Accelerating Oncology Execution

4 months / oncodaily

Back to Top / Sat, April 11, 2026, 4:22 am / permalink 22055 / 3 stories in 4 months /




Related Stories

UCB acquires Candid for $2B to pursue T‑cell engager therapies / 3 months

Merck and Moderna report positive phase‑3 melanoma vaccine results / 10 days

Belzutifan plus lenvatinib outperforms cabozantinib in advanced RCC / 12 days

First patient enrolled in AACR-ADOPT-GEA gastroesophageal cancer trial / 22 days

Phase 1 trial shows cevostamab activity in relapsed multiple myeloma / 5 wks

EMERALD‑3 tests tremelimumab/durvalumab combos for embolisation‑eligible HCC / 1 month

Long‑term Botensilimab+Balstilimab data show durable responses in MSS CRC / 2 months

StackHealth RSS

You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Product Recall, Medicare Advantage (not listed), Cancer Research, Health Disparities and look for the RSS link.




↑

NorthFeed Inc. Terms and Conditions / Privacy Policy

Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.